Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.550
+0.010 (0.65%)
Feb 11, 2026, 1:54 PM EST - Market open
Revelation Biosciences Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Revelation Biosciences in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Revelation Biosciences.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $28,800 → $86,400 | Strong Buy | Maintains | $28,800 → $86,400 | +5,574,093.55% | Feb 14, 2023 |
| Roth Capital | Roth Capital | Strong Buy Initiates $2,419,200 | Strong Buy | Initiates | $2,419,200 | +156,077,319.35% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-37.33
from -1.05K
EPS Next Year
-6.65
from -37.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -24.82 | -5.00 | ||||
| Avg | -37.33 | -6.65 | ||||
| Low | -48.57 | -8.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.